Immunotherapies

Immunology
Immunotherapies
Market Movers

Vera Therapeutics, Inc. (VERA): Promising Therapies for Immunological Needs

Vera Therapeutics, Inc. (VERA) is a clinical-stage biotechnology company focused on developing transformative therapies for patients with serious immunological diseases. Their mission is to address unmet medical needs by creating innovative treatments targeting immune system pathways. Vera’s expertise lies in identifying and advancing therapies that have the potential to significantly improve patient outcomes in conditions […]

Read More
Biomedical
Biopharmaceuticals
Immunology Biopharmaceutical
Immunotherapies
Stock Market Today
Top Stock Market News

Stock Market Update – Bullish Pause – BioMed Stock Moving

Market conditions are Mildly bullish in a Bear Market as of 2022-11-28. This means traders and investors should consider trading with a Neutral or Bullish bias by buying stocks and setting tight stops. The rank of the Bear Market is -16.70 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]

Read More
Daily Rundown
Diversified Natural Resource
Employment Services
Equity REIT
High Speed Data
Immunotherapies
Real Estate Investment Trust (REIT)

Immunotherapies, Employment, High Speed Data, REIT, Diversified Natural Resource

Gritstone bio, Inc. (GRTS) Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder […]

Read More
Biopharmaceuticals
Daily Rundown
Dry Bulk Shipping
Immunotherapies
MRNA Vaccines
RNA Biotechnology
Shipping Transportation

Shipping, RNA Vaccines, Biotech, Construction, Immunotherapies

Grindrod Shipping Holdings Ltd. (GRIN) Grindrod Shipping Holdings Ltd., an international shipping company, owns, charters-in, and operates a fleet of dry bulk carriers and tankers worldwide. It operates a fleet of 23 owned dry bulk carriers and 8 long-term chartered-in dry bulk carriers that transport a range of bulk and breakbulk commodities, including ores, coal, […]

Read More
Amplifiers
Clinical Research
Daily Rundown
Digital Printing
Electric Mobility
Electric Vehicles
EV Charging
Immunotherapies

Immunotherapies, Amplifiers, Digital Printing, Electric Mobility, Clinical Research

BioNTech SE (BNTX) BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer. AmpliTech Group, Inc. (AMPG) […]

Read More
Biotech
Cancer
Cancer Biopharmaceuticals
Coronavirus
COVID-19
Dividends
Economy
Fibonacci Retracement
Fundamental Analysis
HeathCare
Immunology Biopharmaceutical
Immunotherapies
Pharmaceuticals
RNA Biotechnology
Technical Analysis
Tumor-Specific Cancer Immunotherapies
Vaccines
Value Investing
Value Stocks

PFE is down about 20% in the last three months, and that’s a good thing for value-focused investors

As recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]

Read More
Biomedical
Biopharmaceuticals
Biotech
Cancer
COVID-19
Immunotherapies
Trade Of The Day

Why BioNTech (BNTX) Is Blasting Higher

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial […]

Read More